Investigation of CYP3A induction by PF‐05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response

PF‐05251749 is a dual inhibitor of casein kinase 1 δ/ε under clinical development to treat disruption of circadian rhythm in Alzheimer's and Parkinson's diseases. In vitro, PF‐05251749 (0.3–100 μM) induced CYP3A in cryopreserved human hepatocytes, demonstrating non‐saturable, dose–dependen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jian, Gaudreault, Francois, Johnson, Nathaniel, Lin, Zhiwu, Nouri, Parya, Goosen, Theunis C., Sawant‐Basak, Aarti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468555/
https://www.ncbi.nlm.nih.gov/pubmed/35730131
http://dx.doi.org/10.1111/cts.13352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468555/
https://www.ncbi.nlm.nih.gov/pubmed/35730131
http://dx.doi.org/10.1111/cts.13352

Ejemplares similares